Health Care

Consumer Goods Consumer Services Economy Energy Finance Health Care How To Invest Industrials Materials

EV Battery Market worth $168.95 billion by 2035| MarketsandMarkets™

DELRAY BEACH, Fla., June 9, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the EV Battery Market is projected to reach USD 168.95 billion by 2035, from USD 103.04 billion in 2026, with...

Industrials prnewswire -

Vice President Pence Joins Robert Costa at the National Press Club on June 15

WASHINGTON, June 9, 2026 /PRNewswire/ -- Vice President Mike Pence will discuss his new...

Consumer Services prnewswire -

Uxin to Report First Quarter 2026 Financial Results on June 16, 2026

BEIJING, June 9, 2026 /PRNewswire/ -- Uxin Limited ("Uxin" or the "Company") (Nasdaq: UXIN),...

Consumer Goods prnewswire -

Trilogy Metals Announces Commencement of 2026 Summer Field Program at the Upper Kobuk Mineral Projects in Alaska

VANCOUVER, BC, June 9, 2026 /CNW/ - Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ)...

Mining prnewswire -

U.S. GoldMining Provides Updates on the 2026 Exploration Program and District Infrastructure Catalysts at its 100% Owned Whistler Project, Alaska

ANCHORAGE, Alaska, June 9, 2026 /CNW/ - U.S. GoldMining Inc. (NASDAQ: USGO) ("U.S. GoldMining" or...

Energy prnewswire -

Latest

Dayspring Pharma Announces Positive Topline Results from Phase II Clinical Trial of CG2001 for the Treatment of Androgenetic Alopecia (AGA)

SEOUL, South Korea, June 7, 2026 /PRNewswire/ -- Dayspring Pharma, a clinical-stage biotechnology company focused on innovative dermatology therapies, announced the first public disclosure of...

Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37...

HONG KONG, June 7, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces the presentation of three key studies at the American Diabetes...

GNI Group to Acquire Ayumi Pharmaceutical Holdings, Expanding Its Position as a Global Biopharmaceutical Company

Transaction Establishes a Large-Scale Pharmaceutical Platform in Japan and Strengthens Commercial Capabilities Across Key Therapeutic Areas

Transaction Establishes a Large-Scale Pharmaceutical Platform in Japan and Strengthens Commercial Capabilities Across Key Therapeutic Areas

LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China

The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated in Q1 2027

The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated in Q1 2027

VolitionRx Announces Pricing of $4.6 Million Public Offering

$4.6 million upfront with up to an additional $2.3 million of potential aggregate gross proceeds upon the full exercise of warrantsHENDERSON, Nev., June 7,...

Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide

NEW ORLEANS, June 8, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences"), a commercial-stage biopharmaceutical company focused on discovering and developing innovative...

Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting...

Ingelheim, Germany - Boehringer Ingelheim today announced positive results from two global Phase III trials of its glucagon/GLP-1 dual agonist survodutide (BI 456906), SYNCHRONIZE-1 and SYNCHRONIZE-MASLD.^2,4 The results demonstrate survodutide’s potential to reduce weight and therefore improve metabolic health in two distinct populations: adults living with obesity or overweight, without type 2 diabetes (SYNCHRONIZE-1),²and adults with overweight or obesity with metabolic dysfunction-associated steatotic liver disease (MASLD) with evidence of inflammation and or fibrosis (SYNCHRONIZE-MASLD).⁴ Full results from SYNCHRONIZE-1 and SYNCHRONIZE-MASLD were presented today at the American Diabetes Association’s (ADA) 2026 Scientific Sessions and published simultaneously in The New England Journal of Medicine and Nature Medicine respectively.^5,6

Once-Weekly Drug Demonstrates Promising Dual Benefits in Obesity and Metabolic Health

Injectable Offers Potential to Reduce Fatty Liver Diseases and Improve Health Markers in AdultsNEW ORLEANS, June 7, 2026 /PRNewswire/ -- New data highlight the potential...

Zealand Pharma announces Boehringer Ingelheim’s survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while...

Company announcement No. 21 / 2026

Antag Therapeutics presents positive Phase 1 results at the 2026 Scientific Sessions of the American Diabetes Association for AT7687, a first-in-class GIPR antagonist

Copenhagen, Denmark, 7 June 2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment through GIP receptor antagonism, today presented key Phase 1 and preclinical data for AT7687 at the 2026 Scientific Sessions of the American Diabetes Association^®, held in New Orleans, Louisiana from June 5-8, 2026.

Lilly’s Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage...

In ATTAIN-1, women in perimenopause taking Foundayo lost up to 30.4 lbs (14.4%) and those in post-menopause lost up to 28.2 lbs (14.1%)In ATTAIN-2, women taking Foundayo lost significant...

Wegovy® pill prescriptions surpass 3 million, 1 filled roughly every 5 seconds, bringing GLP-1 therapy to people with obesity previously untreated, while Novo Nordisk...

Three million prescriptions for Wegovy® pill since launch on January 5th serves as another milestone in one of the strongest US pharmaceutical launches by...

Vision Insurance After Retirement (2026): VSP Vision Care Named Leading Option for Retiree Eye Coverage by Expert Consumers

NEW YORK, June 7, 2026 /PRNewswire/ -- A recent analysis from Expert Consumers highlights VSP® Vision Care as a leading option for vision insurance...

The American Diabetes Association Announces Winners of the Innovation Challenge

NEW ORLEANS, June 6, 2026 /PRNewswire/ -- Today, from the main stage at the organization's 2026 Scientific Sessions, the American Diabetes Association® (ADA) announced...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Comments

This field is for validation purposes and should be left unchanged.

HomePress ReleasesHealth Care

EV Battery Market worth $168.95 billion by 2035| MarketsandMarkets™

Vice President Pence Joins Robert Costa at the National Press Club on June 15

U.S. GoldMining Provides Updates on the 2026 Exploration Program and District Infrastructure Catalysts at its 100% Owned Whistler Project, Alaska

Health Care

EV Battery Market worth $168.95 billion by 2035| MarketsandMarkets™

Vice President Pence Joins Robert Costa at the National Press Club on June 15

Uxin to Report First Quarter 2026 Financial Results on June 16, 2026

Trilogy Metals Announces Commencement of 2026 Summer Field Program at the Upper Kobuk Mineral Projects in Alaska

U.S. GoldMining Provides Updates on the 2026 Exploration Program and District Infrastructure Catalysts at its 100% Owned Whistler Project, Alaska

Dayspring Pharma Announces Positive Topline Results from Phase II Clinical Trial of CG2001 for the Treatment of Androgenetic Alopecia (AGA)

Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37...

GNI Group to Acquire Ayumi Pharmaceutical Holdings, Expanding Its Position as a Global Biopharmaceutical Company

LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China

VolitionRx Announces Pricing of $4.6 Million Public Offering

Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide

Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting...

Once-Weekly Drug Demonstrates Promising Dual Benefits in Obesity and Metabolic Health

Zealand Pharma announces Boehringer Ingelheim’s survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while...

Antag Therapeutics presents positive Phase 1 results at the 2026 Scientific Sessions of the American Diabetes Association for AT7687, a first-in-class GIPR antagonist

Lilly’s Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage...

Wegovy® pill prescriptions surpass 3 million, 1 filled roughly every 5 seconds, bringing GLP-1 therapy to people with obesity previously untreated, while Novo Nordisk...

Vision Insurance After Retirement (2026): VSP Vision Care Named Leading Option for Retiree Eye Coverage by Expert Consumers

The American Diabetes Association Announces Winners of the Innovation Challenge

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us